ClinicalTrials.gg
RecruitingNCT06908304Updated Jan 12, 2026

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

A Phase 3 interventional study of 6-Thio-2'-Deoxyguanosine and Cemiplimab in Carcinoma, Non-Small -Cell Lung, sponsored by Maia Biotechnology. Recruiting at 15 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Maia Biotechnology · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung — 18 open to participants now, 22 under way, 3 of them phase 3. cemiplimab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
5th of 29
300 · median 61
Started
2025
with 9 others
Phase 3
5 of 29
2 open now
Primary completion
2027-07
later than 3 of 21 live
Registered
19th of 29
by date

Among the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by planned enrollment, is one of 10 that started in 2025, is one of 5 in phase 3, reaches primary completion later than 3 of the 21 other live ones, and was the 19th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

18 of the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About cemiplimab

cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

THIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®). THIO is preferentially incorporated into telomeres sequence in telomerase-positive cells leading to rapid telomere uncapping, genomic instability, and cell death.

Cemiplimab is a programmed cell death protein 1 (PD-1) inhibitor recently approved as a first-line treatment for patients with locally advanced or metastatic NSCLC with 50% or more PD-L1 expression. It is hypothesized that THIO administration prior to cemiplimab would restore tumor responses to immunotherapy in subjects who either developed resistance or relapsed after receiving first line treatment with an immune check point inhibitor.

03

Conditions studied

  • Carcinoma, Non-Small -Cell Lung

Keywords

  • squamous cell carcinoma
  • Adenocarcinoma
  • Non-Small Cell Lung Carcinoma
  • Non-Small Cell Lung Cancer
  • Large Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age at the time of signing the Form (ICF) prior to initiation of any study specific activities/procedures.

    Disease Characteristics

  2. Stage 3b or 4 or cytologically confirmed NSCLC. Note: Stage is determined at the time of diagnosis.
  3. Two (2) for advanced/ disease, including an ICI (/PD-L1) and a platinum-based chemotherapy (given in combination or in separate lines) for advanced/metastatic disease.

    Note: The combination of primary therapy followed by maintenance is considered as one line of therapy. Prior treatment with docetaxel is preferred (but not mandated) and is a pre-specified stratification factor.

  4. Documented progression or intolerance following the most recent line of therapy.

    • Stage 4 subjects - must have progressed or after first-line treatment.
    • Stage 3b subjects - must have already failed, or be ineligible for, local, curative-intent therapy including surgery, and/or chemoradiation.

    Note: Local, curative-intent therapy including surgery, and/or chemoradiation is not considered a treatment line in the advanced setting.

  5. Documented secondary resistance to the prior ICI treatment, as defined by the SITC IRTF (Kluger, 2020):

    Resistance phenotype Drug exposure requirements Best response Confirmation scan for PD requirement Confirmation scan timeframe Secondary resistance ≥ 6 months CR, PR, SD for > 6 months Yes [1] At least 4 weeks after disease progression (per V1.1) [1] Other than when tumor growth is very rapid, and subjects are deteriorating clinically.

    Abbreviations: CR=complete response; PD=progressive disease; PR=partial response; SD=stable disease

  6. No prior targeted therapy for driver mutations.
  7. At least one measurable target lesion that meets the definition of RECIST v1.1, with documented progression following the most recent line of therapy.
  8. An sample (formalin fixed paraffin-embedded [FFPE] tissue block or unstained slides) is required if tissue is available at baseline.

    Note: The sample does not need to be received by the central laboratory prior to Cycle 1, Day 1 (C1D1). Subjects without archival tissue available at baseline may be eligible with Medical Monitor approval.

    Diagnostic Assessments

  9. (ECOG) performance status of 0-1.
  10. Demonstrate adequate organ function as defined below. All screening laboratories should be performed up to 14 days before initiating IP:

    Bone marrow function:

    ○ ≥ 1500/mm3, ≥ 9.0 g/dL, count ≥ 100,000/mm3

    Liver function:

    • Total ≤ 1.5 x the (ULN), up to ≤ 3 × ULN if due to Gilbert's syndrome
    • (ALT) and aspartate aminotransferase (AST) ≤ 1.5 × ULN.

    Note: For subjects with liver metastases present at baseline, ALT and/or AST ≤ 3 × ULN is permitted.

    Renal function:

    ○ (CrCl) ≥ 60 mL/min calculated by the Cockcroft-Gault formula using actual body weight (see Table 18) or 24-hour urine collection.

    Gender and Reproductive Requirements

  11. Women of (WOCBP) must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 72 hours prior to receiving the first administration of IP.
  12. use:

In the THIO / cemiplimab arm:

  • WOCBP must agree to use a highly effective birth control and refrain from oocyte donation during the study (prior to the first dose with THIO, for the duration of the treatment with THIO, and for six months after the last dose of study treatment, if conception is possible during this interval).
  • Unless permanently sterile by bilateral orchidectomy, male subjects and WOCBP partners of male subjects should use a combination of the methods specified for female subjects in Appendix 4, Section 10.4 along with a male condom, from start of study treatment, for the duration of the treatment, and for six months after the last dose of study treatment. Male subjects should also refrain from sperm donation during this time.

In the single-agent chemotherapy arm: For WOCBP, male subjects and WOCBP partners of male subjects, contraception requirements should follow the relevant product's package labelling and standard of care.

Note: Contraception use by men or women in both treatment arms should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Informed Consent 13. Capable and willing to give signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion criteria

Exclusion Criteria:

  1. For subjects who have received prior treatment with a : primary resistance to prior checkpoint inhibitor, as defined by the SITC IRTF (Kluger, 2020):

    Resistance phenotype Drug exposure requirements Best response Confirmation scan for PD requirement Confirmation scan timeframe Primary resistance ≥ 6 weeks PD; SD for \< 6 months Yes [1] At least 4 weeks after initial disease progression (per v1.1) [1] Other than when tumor growth is very rapid, and subjects are deteriorating clinically.

    Abbreviations: CR=complete response; PD=progressive disease; PR=partial response; SD=stable disease Note: Subjects with drug exposure > 6 weeks who achieved a partial or complete response then progressed before six months, would still be eligible.

  2. Untreated or symptomatic central nervous system (CNS) . Note: Subjects with treated asymptomatic are eligible.
  3. Prior chemotherapy and/or non-biologic targeted therapy within 28 days, or biologic targeted therapy, immunotherapy, and/or radiation therapy within 42 days prior to start of study treatment.

    Note: Subjects who receive targeted radiation therapy for localized palliative care may be eligible to start study treatment earlier than 42 days with Medical Monitor agreement.

  4. Prior treatment with cemiplimab.
  5. Prior treatment with a targeted therapy for an epidermal growth factor receptor (EGFR) mutation.
  6. Received blood, red blood cell or transfusion within 14 days prior to start of study treatment.
  7. Any live, attenuated, inactivated or research vaccines within 30 days prior to start of study treatment.

    Note: Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed.

  8. Prior hematopoietic stem cell transplant or solid organ transplant.
  9. Undergone major surgery within 28 days prior to start of study treatment. Medical conditions
  10. Have not recovered to Grade ≤ 1 from adverse events due to prior anti-cancer treatment.
  11. Ongoing immune-related / stimulated adverse events (irAEs) from other agents or required permanent discontinuation of prior ICIs due to irAEs.

    Note: Subjects with resolved irAE may be allowed to enroll following consultation with the Medical Monitor.

  12. Active gastrointestinal bleeding as evidenced by either hematemesis or melena.
  13. History of another concurrent other than the present condition (except nonmelanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off all therapy for that disease for a minimum of three years.
  14. A condition requiring systemic treatment with either (> 10 mg daily prednisone equivalents) or other medications within 14 days prior to start of study treatment.

    Note: Inhaled or topical steroids, adrenal replacement doses 10 mg daily prednisone equivalents, and systemic corticosteroids to manage adverse events are permitted in the absence of active disease.

  15. Active, uncontrolled bacterial, viral or fungal infections, requiring systemic therapy within 14 days of screening.
  16. Positive for (HIV) (HIV 1/2 antibodies), active or .
  17. Significant cardiovascular impairment (history of Functional Classification System Class III or IV) or a history of myocardial infarction or unstable angina within the past six months prior to start of study treatment.
  18. corrected for heart rate (using Fridericia's correction formula; QTcF) > 480 msec at screening (based on average of triplicate [ECGs] at baseline).

    Note: If the QTc is prolonged in a subject with a pacemaker or bundle branch block, the subject may be enrolled in the study if confirmed by the Medical Monitor.

  19. Active autoimmune diseases or history of autoimmune diseases that may relapse, with the following exceptions:

    • Controlled Type 1 diabetes
    • Hypothyroidism (provided it is managed with hormone replacement therapy only)
    • Controlled celiac disease
    • Skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, or alopecia)
    • Any other disease that is not expected to recur in the absence of external triggering factors.
  20. Pregnancy or lactating.
  21. A serious nonmalignant disease (e.g., psychiatric, substance abuse, uncontrolled intercurrent illness, interstitial lung disease etc.) that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.
  22. Any other condition that, in the opinion of the Investigator, would prohibit the subject from participating in the study.

    Prior / concurrent clinical study experience

  23. Currently enrolled in a clinical study involving another product or nonapproved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

    Other

  24. History of allergy to of THIO, cemiplimab or any of the chemotherapies under study.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    THIO + Cemiplimab Arm

    THIO 60mg, 30-min IV infusions, Days 1-3 (180 mg/Cycle) Cemplimab 350 mg, 30-min IV infusion, Day 5 3-Week Cycle

    Drug: 6-Thio-2'-Deoxyguanosine · Drug: Cemiplimab

  • Active comparator
    Investigator's choice of single-agent chemotherapy (vinorelbine, gemcitabine, or docetaxel)

    Chemotherapy Agent \[1\] Dosing Regimen No. of Subjects (Planned) Option 1: Vinorelbine 30 mg/m2 IV on D1, D8, and D15 Q3W \~150 \[3\] Option 2: Gemcitabine 1250 mg/m2 IV on D1 and D8 Q3W Option 3: Docetaxel 75 mg/m2 IV on D1 Q3W \[2\] Abbreviations: D = day (within a 21-day cycle); IV= intravenous; Q3W=every 3 weeks (21-day cycles) 1. Standard of Care (for example vinorelbine, gemcitabine, or docetaxel chemotherapy, if not previously exposed, per Investigator's Choice) 2. Docetaxel 60-65 mg/m2 permitted based on country-specific approvals. 3. Within the control arm, there are no limits on the number of subjects who can be treated with any of the chemotherapy agents.

    Drug: Docetaxel · Drug: Vinorelbine · Drug: Gemcitabine alone

Interventions

  • small molecule telomere targeting agent

    Also known as: 6-thio-dG, THIO, ateganosine

  • programmed cell death protein 1 (PD-1) inhibitor

    Also known as: LIBTAYO®

  • Chemotherapy drug; inhibits cell division by stabilizing microtubules. Used for breast, lung, and prostate cancers.

    Also known as: Taxotere, Docecad

  • Chemotherapy drug; disrupts microtubule formation, inhibiting cell division. Used for non-small cell lung cancer and breast cancer.

    Also known as: Navelbine, Vinorelbine tartrate

  • Chemotherapy drug; inhibits DNA synthesis. Used for pancreatic, lung, breast, and ovarian cancers.

    Also known as: Gemzar

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival as defined as the time from randomization to death from any cause.

    Time frame: Within 2 Years

Secondary outcomes

  1. Objective Radiographic Response

    Objective Radiographic Response as defined as the proportion of subjects demonstrating a confirmed objective response of complete response or partial response.

    Time frame: Within 2 Years

  2. Disease Control Rate

    Disease Control Rate as defined as the proportion of subjects demonstrating complete response, partial response, or stable disease after 2 treatment cycles.

    Time frame: Within 2 Years

  3. Duration of Response

    Duration of Response as defined as the time from response complete response or partial response to progressive disease.

    Time frame: Within 2 Years

  4. Progressive Free Survival

    Progressive Free Survival as defined as the time from randomization to the first occurrence of progressive disease or death from any cause, whichever occurs first.

    Time frame: Within 2 Years

  5. Treatment Emergent Adverse events and Serious Adverse Events

    Incidence of Treatment Emergent Adverse events and Serious Adverse Events leading to discontinuation of study medication (THIO and/or cemiplimab) and/or withdrawal from the study.

    Time frame: Within 2 Years

Other outcomes

  1. Exploratory Objectives

    Pharmacokinetic tests to determine THIO concentration

    Time frame: Within 2 Years

  2. Exploratory Objectives

    Pharmacodynamics parameters based on PCR-Based quantitative Telomeric Repeat Amplification Protocol assay in circulating tumor cells.

    Time frame: Within 2 Years

  3. Exploratory Objectives

    To assess blood levels of interleukin 6.

    Time frame: Within 2 Years

  4. Exploratory Objectives

    To assess blood levels of high sensitivity C-reactive protein.

    Time frame: Within 2 Years

  5. Exploratory Objectives

    To assess blood levels of carcinoembryonic antigen.

    Time frame: Within 2 Years

07

Study locations

15 of 15 sites recruiting
  • Centrum Medyczne Pratia
    Poznan, Poland
    Recruiting
    • Marek Kotlarski · Principal investigator
  • Oncolab S.R.L.
    Craiova, Romania
    Recruiting
    • Dan Lungulescu · Principal investigator
  • Spitalul Clinic Municipal de Urgenta Timisoara/ Clinica de Oncologie Medicala
    Timișoara, Romania
    Recruiting
    • Razvan Bobora · Principal investigator
  • Changhua Christian Hospital (CCH)
    Changhua, Taiwan
    Recruiting
    • Sheng-Hao Lin · Principal investigator
  • Taipei Tzu Chi Hospital
    Chiayi City, Taiwan
    Recruiting
    • Chun-Liang Lai · Principal investigator
  • Chang-Gung Memorial Hospital - KaoHsiung
    Kaohsiung City, Taiwan
    Recruiting
    • Chien-Hao Lai · Principal investigator
  • Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
    Kaohsiung City, Taiwan
    Recruiting
    • Jen-Yu Hung · Principal investigator
  • Chung Shan Medical University Hospital (CSMUH)
    Taichung, Taiwan
    Recruiting
    • Gee-Chen Chang · Principal investigator
  • Taipei Medical University Hospital (TMUH)
    Taipei, Taiwan
    Recruiting
    • Shih-Hsin Hsiao · Principal investigator
  • Tri-Service General Hospital
    Taipei, Taiwan
    Recruiting
    • Chen-Liang Tsai · Principal investigator
  • Chang-Gung Memorial Hospital - Linko
    Taoyuan City, Taiwan
    Recruiting
    • Wen-Cheng Change · Principal investigator
  • Medicalpark Hastanesi
    Adana, Turkey (Türkiye)
    Recruiting
    • Ahmet Sezel · Principal investigator
  • Liv Hospital
    Ankara, Turkey (Türkiye)
    Recruiting
    • Saddettin Kilickap · Principal investigator
  • Göztepe Süleyman Yalçın Şehir Hastanesi
    Istanbul, Turkey (Türkiye)
    Recruiting
    • Mahmut Gümüş · Principal investigator
  • İstinye University
    Istanbul, Turkey (Türkiye)
    Recruiting
    • Erkan Kayikcioglu · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jul 2027, 19 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 19 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2025
First posted
Apr 3, 2025
StartActual
Dec 8, 2025
Primary completionEst.
Jul 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06908304
Lead sponsor
Maia Biotechnology
Responsible party
Sponsor
First posted
Apr 3, 2025
Start date
Dec 8, 2025
Primary completion
Jul 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 12, 2026

Study contacts

Matthew Failor
Contact
mfailor@maiabiotech.com
704-936-8435
Imy Chiu
Contact
ichiu@maiabiotech.com
Victor Zaporojan, Medical Doctor
study director · MAIA Biotechnology Senior Medical Director

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alpha-2'-deoxythioguanosine · Cemiplimab

Start the discussion